首页 > 最新文献

Allergy and asthma proceedings最新文献

英文 中文
A case of a rash after tetanus-diphtheria-pertussis and meningococcal vaccination. 一例接种破伤风-白喉-百日咳-脑膜炎球菌疫苗后出疹的病例。
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240083
Leonardo Salazar, Joanne Acevedo, Fiona Adame, Brent Kelly, Cleavon Covington

We present a case of a 12-year-old healthy girl who presented with acute onset of dry, hyperpigmented, and raised pruritic rash. The lesions initially presented on her thighs then progressed to the trunk and arms hours after receiving the tetanus-diphtheria-pertussis (Tdap) and meningococcal vaccine. After a poor response to medium potency topical steroids, a biopsy specimen was taken, which led to our diagnosis. Current literature reports this condition occurring after Tdap; measles, mumps, and rubella; and COVID-19 vaccinations; but, to our knowledge, not after meningitis vaccines. The role that vaccines play in the pathophysiology remains unclear. This condition may get mistaken for an allergic reaction and lead to vaccine avoidance.

我们为您介绍一例 12 岁健康女孩的病例,她在发病初期出现干燥、色素沉着和隆起的瘙痒性皮疹。皮损最初出现在她的大腿上,在接种破伤风-白喉-百日咳(Tdap)和脑膜炎球菌疫苗数小时后,皮损发展到躯干和手臂。在对中等药效的局部类固醇反应不佳后,我们对她进行了活组织检查,最终确诊了她的病情。据目前的文献报道,接种百白破疫苗、麻疹、腮腺炎和风疹疫苗以及 COVID-19 疫苗后会出现这种情况,但据我们所知,接种脑膜炎疫苗后不会出现这种情况。疫苗在病理生理学中的作用尚不清楚。这种情况可能会被误认为是过敏反应,从而导致避免接种疫苗。
{"title":"A case of a rash after tetanus-diphtheria-pertussis and meningococcal vaccination.","authors":"Leonardo Salazar, Joanne Acevedo, Fiona Adame, Brent Kelly, Cleavon Covington","doi":"10.2500/aap.2024.45.240083","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240083","url":null,"abstract":"<p><p>We present a case of a 12-year-old healthy girl who presented with acute onset of dry, hyperpigmented, and raised pruritic rash. The lesions initially presented on her thighs then progressed to the trunk and arms hours after receiving the tetanus-diphtheria-pertussis (Tdap) and meningococcal vaccine. After a poor response to medium potency topical steroids, a biopsy specimen was taken, which led to our diagnosis. Current literature reports this condition occurring after Tdap; measles, mumps, and rubella; and COVID-19 vaccinations; but, to our knowledge, not after meningitis vaccines. The role that vaccines play in the pathophysiology remains unclear. This condition may get mistaken for an allergic reaction and lead to vaccine avoidance.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"456-459"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstracts presented at the Eastern Allergy Conference May 30-June 2, 2024, Palm Beach, Florida. 2024 年 5 月 30 日至 6 月 2 日在佛罗里达州棕榈滩举行的东部过敏大会摘要。
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2025.46.240097
{"title":"Abstracts presented at the Eastern Allergy Conference May 30-June 2, 2024, Palm Beach, Florida.","authors":"","doi":"10.2500/aap.2025.46.240097","DOIUrl":"https://doi.org/10.2500/aap.2025.46.240097","url":null,"abstract":"","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"461-469"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of pediatric patients with suspected nonsteroidal anti-inflammatory drug hypersensitivity. 对疑似非甾体类抗炎药过敏的儿科患者进行评估。
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240061
Selcuk Dogan, Aysegul Ertugrul, Murat Ozer, Ezgi Ulusoy Severcan, Seda Sirin, Serap Ozmen

Background: Beta-lactam antibiotics are the most common cause of hypersensitivity reactions to medications, followed by nonsteroidal anti-inflammatory drugs (NSAID). Objective: The aim of this study was to classify children with hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAID-H) according to the latest updates. Methods: ENDA recommendations were used to evaluate all patients with suspected NSAID-H. Children were classified as either selective responders (SR) or cross-intolerant based on the results of the drug provocation test (DPT). Results: Sixty-seven patients with suspected NSAID-H were evaluated in this study. NSAID-H was confirmed in 20 patients (29.9%). Among the 20 patients diagnosed with NSAID-H, 15 were classified according to the 2018 EAACI/ENDA Position Paper. Twelve patients (80%) were classified as cross-intolerant and 3 (20%) as SRs. NSAID-H was confirmed in 4 of 37 patients (10.8%) ages <10 years and 16 of 30 patients (53.3%) ages >10 years (p < 0.001). Twelve patients ages >10 years were classified. Cross-intolerance was detected in nine patients (66.6%). In patients >10 years of age, NSAID-induced urticaria/angioedema (NIUA) (16.7%) was the most common type in the group with classifiable cross-intolerant. In addition, NSAID-exacerbated respiratory disease was detected in one patient. Conculsion: Ibuprofen is the most common NSAID-H drug used in children. NIUA is the most common reaction. In pediatric allergy, hypersensitivity to NSAIDs is a challenging diagnostic issue. Hypersensitivity to NSAIDs poses a challenging diagnostic issue in pediatric allergies. The oral challenge test is the main diagnostic tool; however, in clinical practice, performing multiple challenge tests is difficult.

背景:β-内酰胺类抗生素是导致药物过敏反应的最常见原因,其次是非类固醇抗炎药(NSAID)。研究目的本研究旨在根据最新进展对非甾体抗炎药(NSAID-H)超敏反应儿童进行分类。方法:采用ENDA建议对所有儿童进行评估:采用ENDA建议对所有疑似NSAID-H患者进行评估。根据药物激发试验(DPT)的结果,将儿童分为选择性反应者(SR)或交叉耐受者。结果本研究共评估了 67 名疑似非甾体抗炎药物-H 患者。有 20 名患者(29.9%)确诊为 NSAID-H。在确诊为 NSAID-H 的 20 名患者中,有 15 人根据 2018 年 EAACI/ENDA 立场文件进行了分类。12名患者(80%)被归类为交叉不耐受者,3名患者(20%)被归类为SRs。在 37 名年龄为 10 岁(p 10 岁)的患者中,有 4 人(10.8%)被确认为非甾体抗炎药耐受者。9名患者(66.6%)被检测出交叉耐受。在年龄大于 10 岁的患者中,非甾体抗炎药诱发的荨麻疹/水肿(NIUA)(16.7%)是可归类的交叉不耐受人群中最常见的类型。此外,在一名患者中还发现了非甾体抗炎药加重的呼吸道疾病。结肠炎:布洛芬是儿童最常用的非甾体抗炎药。NIUA是最常见的反应。在儿科过敏症中,对非甾体抗炎药过敏是一个具有挑战性的诊断问题。对非甾体抗炎药过敏是儿科过敏症诊断中的一个难题。口服挑战试验是主要的诊断工具;但在临床实践中,进行多次挑战试验是很困难的。
{"title":"Assessment of pediatric patients with suspected nonsteroidal anti-inflammatory drug hypersensitivity.","authors":"Selcuk Dogan, Aysegul Ertugrul, Murat Ozer, Ezgi Ulusoy Severcan, Seda Sirin, Serap Ozmen","doi":"10.2500/aap.2024.45.240061","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240061","url":null,"abstract":"<p><p><b>Background:</b> Beta-lactam antibiotics are the most common cause of hypersensitivity reactions to medications, followed by nonsteroidal anti-inflammatory drugs (NSAID). <b>Objective:</b> The aim of this study was to classify children with hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAID-H) according to the latest updates. <b>Methods:</b> ENDA recommendations were used to evaluate all patients with suspected NSAID-H. Children were classified as either selective responders (SR) or cross-intolerant based on the results of the drug provocation test (DPT). <b>Results:</b> Sixty-seven patients with suspected NSAID-H were evaluated in this study. NSAID-H was confirmed in 20 patients (29.9%). Among the 20 patients diagnosed with NSAID-H, 15 were classified according to the 2018 EAACI/ENDA Position Paper. Twelve patients (80%) were classified as cross-intolerant and 3 (20%) as SRs. NSAID-H was confirmed in 4 of 37 patients (10.8%) ages <10 years and 16 of 30 patients (53.3%) ages >10 years (p < 0.001). Twelve patients ages >10 years were classified. Cross-intolerance was detected in nine patients (66.6%). In patients >10 years of age, NSAID-induced urticaria/angioedema (NIUA) (16.7%) was the most common type in the group with classifiable cross-intolerant. In addition, NSAID-exacerbated respiratory disease was detected in one patient. <b>Conculsion:</b> Ibuprofen is the most common NSAID-H drug used in children. NIUA is the most common reaction. In pediatric allergy, hypersensitivity to NSAIDs is a challenging diagnostic issue. Hypersensitivity to NSAIDs poses a challenging diagnostic issue in pediatric allergies. The oral challenge test is the main diagnostic tool; however, in clinical practice, performing multiple challenge tests is difficult.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"e81-e86"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do commercial dog extracts cross-react with Felis domesticus allergen 1. 商用狗提取物是否会与家禽过敏原 1 产生交叉反应。
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240072
Tasha Hellu, Robert Gomez, Samuel Weiss, Derek Smith, Daniel Steigelman

Background: Half of U.S. households own a dog despite 10% of individuals being sensitized to dog. Assessment and treatment options for dog allergy include the use of commercial dog extracts which have inconsistent performance, making diagnosing and managing dog allergy challenging. Contamination of dog extracts with other allergens has previously been reported. Objective: We sought to determine whether commercial dog extracts contain other aeroallergens. Methods: An extract purity and quantification study on acetone precipitated dog hair and dander extract (AP dog) was performed, 6 aeroallergens; Alternaria (Alt a 1), Ragweed (Amb a 1), German Cockroach (Bla g 2), Dust Mite (Der p t), Cat (Fel d 1), and Rye Grass (Lol p 1). Following, conventional dog hair and dander extract (CV dog) and the new ultrafiltered dog hair and dander extract (UF dog) were also assessed based on the initial results of AP dog. SDS-PAGE was performed on all three dog extracts to compare allergen content. Lastly, serology results and aeroallergen immunotherapy prescriptions were compared. Results: The ELISA trays with Alt a 1, Amb a 1, Bla g 2, Der p 1, and Lol p 1 antibodies did not capture AP dog, while the ELISA tray with Fel d 1 antibody captured AP dog, CV dog, and UF dog. SDS-PAGE results of the 3 dog extracts did not reveal a band at the molecular weight for Fel d 1. Conculsion: Contamination of commercial dog extracts was not found. However, our findings are supportive of commercial dog extracts containing a Fel d 1-like dog allergen that is cross-reactive to Fel d 1. Cross-reactivity between commercial dog extracts and Fel d 1 could be responsible for double positivity to cat and dog in serology. Additional studies are needed to better illustrate this Fel d 1-like dog allergen.

背景:尽管有 10% 的人对狗过敏,但美国仍有一半的家庭养狗。狗过敏的评估和治疗方法包括使用商业狗提取物,但其效果并不稳定,因此诊断和管理狗过敏具有挑战性。以前曾有报道称狗提取物受到其他过敏原的污染。目的:我们试图确定商用狗提取物是否含有其他过敏原。方法:对狗提取物的纯度和定量进行研究:对丙酮沉淀的狗毛和皮屑提取物(AP dog)进行了提取物纯度和定量研究,其中包括 6 种空气过敏原:Alternaria (Alt a 1)、Ragweed (Amb a 1)、German Cockroach (Bla g 2)、Dust Mite (Der p t)、Cat (Fel d 1) 和 Rye Grass (Lol p 1)。根据 AP 狗的初步结果,还对传统的狗毛和皮屑提取物(CV 狗)和新型超滤狗毛和皮屑提取物(UF 狗)进行了评估。对所有三种狗提取物进行 SDS-PAGE 分析,以比较过敏原含量。最后,对血清学结果和空气过敏原免疫疗法处方进行了比较。结果:含有 Alt a 1、Amb a 1、Bla g 2、Der p 1 和 Lol p 1 抗体的 ELISA 盘没有捕获 AP 狗,而含有 Fel d 1 抗体的 ELISA 盘捕获了 AP 狗、CV 狗和 UF 狗。3 种狗提取物的 SDS-PAGE 结果未显示 Fel d 1 的分子量带。浓缩:未发现商品狗提取物受到污染。不过,我们的研究结果支持商用狗提取物中含有与 Fel d 1 具有交叉反应性的 Fel d 1 类狗过敏原。商用狗提取物和 Fel d 1 之间的交叉反应可能是血清学中猫和狗双重阳性的原因。要更好地说明这种类似 Fel d 1 的狗过敏原,还需要进行更多的研究。
{"title":"Do commercial dog extracts cross-react with <i>Felis domesticus</i> allergen 1.","authors":"Tasha Hellu, Robert Gomez, Samuel Weiss, Derek Smith, Daniel Steigelman","doi":"10.2500/aap.2024.45.240072","DOIUrl":"10.2500/aap.2024.45.240072","url":null,"abstract":"<p><p><b>Background:</b> Half of U.S. households own a dog despite 10% of individuals being sensitized to dog. Assessment and treatment options for dog allergy include the use of commercial dog extracts which have inconsistent performance, making diagnosing and managing dog allergy challenging. Contamination of dog extracts with other allergens has previously been reported. <b>Objective:</b> We sought to determine whether commercial dog extracts contain other aeroallergens. <b>Methods:</b> An extract purity and quantification study on acetone precipitated dog hair and dander extract (AP dog) was performed, 6 aeroallergens; Alternaria (Alt a 1), Ragweed (Amb a 1), German Cockroach (Bla g 2), Dust Mite (Der p t), Cat (Fel d 1), and Rye Grass (Lol p 1). Following, conventional dog hair and dander extract (CV dog) and the new ultrafiltered dog hair and dander extract (UF dog) were also assessed based on the initial results of AP dog. SDS-PAGE was performed on all three dog extracts to compare allergen content. Lastly, serology results and aeroallergen immunotherapy prescriptions were compared. <b>Results:</b> The ELISA trays with Alt a 1, Amb a 1, Bla g 2, Der p 1, and Lol p 1 antibodies did not capture AP dog, while the ELISA tray with Fel d 1 antibody captured AP dog, CV dog, and UF dog. SDS-PAGE results of the 3 dog extracts did not reveal a band at the molecular weight for Fel d 1. <b>Conculsion:</b> Contamination of commercial dog extracts was not found. However, our findings are supportive of commercial dog extracts containing a Fel d 1-like dog allergen that is cross-reactive to Fel d 1. Cross-reactivity between commercial dog extracts and Fel d 1 could be responsible for double positivity to cat and dog in serology. Additional studies are needed to better illustrate this Fel d 1-like dog allergen.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"447-452"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The safety of initial single therapeutic dose challenge with a 5-day prolonged drug provocation test in children with a history of low-risk non-immediate reactions to beta-lactam antibiotics. 对曾有β-内酰胺类抗生素低风险非即刻反应史的儿童进行初始单次治疗剂量挑战和 5 天延长药物激发试验的安全性。
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240081
Meltem Comert, Ozge Yilmaz Topal, Tugba Guler, Demet Tekcan, Hasibe Artac, Ilknur Kulhas Celik

Background: Although the gold standard for diagnosing beta-lactam antibiotic (BLA) allergy is the drug provocation test (DPT), there is no standardized protocol for children. Objective: We aimed to evaluate the clinical features and DPT results of children with a history of low-risk non-immediate reactions (NIR) to BLA who underwent initial direct single therapeutic dose challenge with a 5-day prolonged DPT. Methods: We retrospectively evaluated children ages 0-18 years with a history of low-risk NIRs to BLAs. On the first day of provocation, a single-dose DPT protocol without any skin test was administered at the clinic. The therapeutic dose was adjusted to not exceed the maximum single-unit dose (MSUD) for age and weight. The DPT protocol was administered with 100% of MSUD. To identify children with delayed reactions, the parents or caregivers were told to continue giving the medication at home for 5 days. Results: One hundred and nine children were included in this study. The median (interquartile range) age of the children was 62.5 months (26.5-94 months). Of the suspected drugs, the main culprit drug was amoxicillin-clavulanic acid for 89 children (81.7%). The most common clinical manifestation was maculopapular exanthema, which occurred in 85 children (78%), and 8 (7.3%) had a positive DPT result. Three children (2.8%) developed a reaction after the first DPT dose. The remaining children continued to use the suspected BLA at home. Five children (4.7%) developed a reaction while using the drug at home. All the children with positive DPT results developed mild cutaneous signs and presented with a reaction to amoxicillin-clavulanic acid. None had a systemic or severe cutaneous reaction. Conclusion: Initial direct single therapeutic dose challenge with a 5-day prolonged DPT is a useful and safe way to assess low-risk NIRs to BLAs in children.

背景:虽然诊断β-内酰胺类抗生素(BLA)过敏的金标准是药物激发试验(DPT),但目前还没有针对儿童的标准化方案。目的:我们旨在评估临床特征和药物激发试验(DPT):我们的目的是评估对 BLA 有低风险非即刻反应 (NIR) 病史的儿童的临床特征和 DPT 结果,这些儿童接受了首次直接单治疗剂量挑战和为期 5 天的延长 DPT。方法:我们回顾性地评估了对 BLA 有低风险非即刻反应史的 0-18 岁儿童。在挑衅的第一天,我们在诊所实施了单剂量 DPT 方案,未进行任何皮试。治疗剂量经过调整,不超过年龄和体重的最大单剂量(MSUD)。白喉、百日咳、破伤风三联疫苗的剂量为 100%。为了找出有延迟反应的儿童,医生告诉家长或看护人继续在家给儿童用药 5 天。结果本研究共纳入 199 名儿童。患儿年龄的中位数(四分位数间距)为 62.5 个月(26.5-94 个月)。在可疑药物中,89 名儿童(81.7%)的主要罪魁祸首是阿莫西林-克拉维酸。85名儿童(78%)最常见的临床表现是斑丘疹性红斑,8名儿童(7.3%)的白喉、百日咳、破伤风三联疫苗(DPT)检测结果呈阳性。有 3 名儿童(2.8%)在服用第一剂 DPT 后出现反应。其余儿童继续在家中使用疑似 BLA。5名儿童(4.7%)在家中使用该药物时出现了反应。白喉、百日咳、破伤风三联疫苗检测结果呈阳性的所有儿童都出现了轻微的皮肤症状,并对阿莫西林-克拉维酸产生了反应。没有人出现全身或严重的皮肤反应。结论用为期 5 天的长效 DPT 进行初始直接单次治疗剂量挑战是评估儿童对 BLA 的低风险近红外反应的一种有用而安全的方法。
{"title":"The safety of initial single therapeutic dose challenge with a 5-day prolonged drug provocation test in children with a history of low-risk non-immediate reactions to beta-lactam antibiotics.","authors":"Meltem Comert, Ozge Yilmaz Topal, Tugba Guler, Demet Tekcan, Hasibe Artac, Ilknur Kulhas Celik","doi":"10.2500/aap.2024.45.240081","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240081","url":null,"abstract":"<p><p><b>Background:</b> Although the gold standard for diagnosing beta-lactam antibiotic (BLA) allergy is the drug provocation test (DPT), there is no standardized protocol for children. <b>Objective:</b> We aimed to evaluate the clinical features and DPT results of children with a history of low-risk non-immediate reactions (NIR) to BLA who underwent initial direct single therapeutic dose challenge with a 5-day prolonged DPT. <b>Methods:</b> We retrospectively evaluated children ages 0-18 years with a history of low-risk NIRs to BLAs. On the first day of provocation, a single-dose DPT protocol without any skin test was administered at the clinic. The therapeutic dose was adjusted to not exceed the maximum single-unit dose (MSUD) for age and weight. The DPT protocol was administered with 100% of MSUD. To identify children with delayed reactions, the parents or caregivers were told to continue giving the medication at home for 5 days. <b>Results:</b> One hundred and nine children were included in this study. The median (interquartile range) age of the children was 62.5 months (26.5-94 months). Of the suspected drugs, the main culprit drug was amoxicillin-clavulanic acid for 89 children (81.7%). The most common clinical manifestation was maculopapular exanthema, which occurred in 85 children (78%), and 8 (7.3%) had a positive DPT result. Three children (2.8%) developed a reaction after the first DPT dose. The remaining children continued to use the suspected BLA at home. Five children (4.7%) developed a reaction while using the drug at home. All the children with positive DPT results developed mild cutaneous signs and presented with a reaction to amoxicillin-clavulanic acid. None had a systemic or severe cutaneous reaction. <b>Conclusion:</b> Initial direct single therapeutic dose challenge with a 5-day prolonged DPT is a useful and safe way to assess low-risk NIRs to BLAs in children.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"e87-e92"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
For the patient. 对病人而言
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240090
{"title":"For the patient.","authors":"","doi":"10.2500/aap.2024.45.240090","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240090","url":null,"abstract":"","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"460"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considering different Montreal Cognitive Assessment cutoff scores for older adults with asthma. 考虑对患有哮喘的老年人采用不同的蒙特利尔认知评估截断分数。
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240045
Gali Moritz, Jacqueline H Becker, Jyoti V Ankam, Kimberly Arcoleo, Matthew Wysocki, Roee Holtzer, Juan Wisnivesky, Paula J Busse, Alex D Federman, Sunit P Jariwala, Jonathan M Feldman

Background: There is a greater prevalence of cognitive impairment among ethnic and/or racial minorities, and cognitive impairment is a barrier to asthma self-management (SM) behaviors and outcomes in older adults. Objective: The aim of this study was to examine the relationship between cognitive impairment, assessed by using the Montreal Cognitive Assessment (MoCA), and asthma SM behaviors and outcomes in a sample of predominantly Black and Latino participants. In addition, we evaluated whether using two different MoCA cutoff scores influenced the association between cognitive impairment and asthma outcomes. Methods: Baseline cross-sectional data were extracted from a longitudinal study of older adults with asthma (N = 165) ages ≥60 years. Cognition was assessed by using the MoCA. Asthma Control Questionnaire, asthma-related quality of life (AQOL), and inhaled corticosteroid (ICS) adherence were assessed by using self-report. ICS dosing was collected through chart review and inhaler technique was observed and rated. Results: Using established MoCA cutoff scores of 23 and 26 yielded 45% and 74% cognitive impairment rates, respectively. Cognitive impairment, defined by using the cutoff score of 23, was significantly associated with worse asthma control (p = 0.04) and worse ICS adherence (p = 0.01). With a cutoff score of 26, only AQOL was significantly associated with cognitive impairment (p = 0.03). Race and/or ethnicity moderated the relationship between cognitive impairment and asthma control with a MoCA cutoff score of 23, and between cognitive impairment and AQOL with a MoCA cutoff score of 26. Conclusion: Cognitive impairment in older adults with asthma is associated with important clinical outcomes, but this relationship is influenced by the cutoff score used to define cognitive impairment.

背景:认知障碍在少数族裔和/或种族中更为普遍,认知障碍是老年人哮喘自我管理(SM)行为和结果的障碍。研究目的本研究旨在通过使用蒙特利尔认知评估(MoCA)来评估认知障碍与哮喘自我管理行为和结果之间的关系,研究对象主要是黑人和拉丁裔参与者。此外,我们还评估了使用两种不同的 MoCA 临界分数是否会影响认知障碍与哮喘结果之间的关系。研究方法我们从一项针对年龄≥60 岁的哮喘老年人(N = 165)的纵向研究中提取了基线横断面数据。认知能力通过 MoCA 进行评估。哮喘控制问卷、哮喘相关生活质量(AQOL)和吸入性皮质类固醇(ICS)依从性通过自我报告进行评估。通过病历审查收集 ICS 剂量,并对吸入器技术进行观察和评分。结果使用已确定的 MoCA 临界分数 23 分和 26 分,认知障碍率分别为 45% 和 74%。截断分数为 23 分时,认知障碍与哮喘控制较差(p = 0.04)和 ICS 依从性较差(p = 0.01)显著相关。以 26 分为临界值时,只有 AQOL 与认知障碍有显著相关性(p = 0.03)。当 MoCA 临界值为 23 分时,种族和/或民族可调节认知功能障碍与哮喘控制之间的关系;当 MoCA 临界值为 26 分时,认知功能障碍与 AQOL 之间的关系。结论患有哮喘的老年人的认知功能障碍与重要的临床结果有关,但这种关系受到用于定义认知功能障碍的临界值的影响。
{"title":"Considering different Montreal Cognitive Assessment cutoff scores for older adults with asthma.","authors":"Gali Moritz, Jacqueline H Becker, Jyoti V Ankam, Kimberly Arcoleo, Matthew Wysocki, Roee Holtzer, Juan Wisnivesky, Paula J Busse, Alex D Federman, Sunit P Jariwala, Jonathan M Feldman","doi":"10.2500/aap.2024.45.240045","DOIUrl":"10.2500/aap.2024.45.240045","url":null,"abstract":"<p><p><b>Background:</b> There is a greater prevalence of cognitive impairment among ethnic and/or racial minorities, and cognitive impairment is a barrier to asthma self-management (SM) behaviors and outcomes in older adults. <b>Objective:</b> The aim of this study was to examine the relationship between cognitive impairment, assessed by using the Montreal Cognitive Assessment (MoCA), and asthma SM behaviors and outcomes in a sample of predominantly Black and Latino participants. In addition, we evaluated whether using two different MoCA cutoff scores influenced the association between cognitive impairment and asthma outcomes. <b>Methods:</b> Baseline cross-sectional data were extracted from a longitudinal study of older adults with asthma (N = 165) ages ≥60 years. Cognition was assessed by using the MoCA. Asthma Control Questionnaire, asthma-related quality of life (AQOL), and inhaled corticosteroid (ICS) adherence were assessed by using self-report. ICS dosing was collected through chart review and inhaler technique was observed and rated. <b>Results:</b> Using established MoCA cutoff scores of 23 and 26 yielded 45% and 74% cognitive impairment rates, respectively. Cognitive impairment, defined by using the cutoff score of 23, was significantly associated with worse asthma control (p = 0.04) and worse ICS adherence (p = 0.01). With a cutoff score of 26, only AQOL was significantly associated with cognitive impairment (p = 0.03). Race and/or ethnicity moderated the relationship between cognitive impairment and asthma control with a MoCA cutoff score of 23, and between cognitive impairment and AQOL with a MoCA cutoff score of 26. <b>Conclusion:</b> Cognitive impairment in older adults with asthma is associated with important clinical outcomes, but this relationship is influenced by the cutoff score used to define cognitive impairment.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"e72-e80"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The utility of shared decision making in the management of hereditary angioedema. 共同决策在遗传性血管性水肿治疗中的实用性。
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240071
Rachel Odin, John Anderson, Joshua Jacobs, Douglas Jones, H Henry Li, William Lumry, Michael Manning, Daniel Soteres, Raffi Tachdjian, William Yang, Jonathan A Bernstein

Background: Hereditary angioedema (HAE) is a complex disorder with a wide array of treatment options. Shared decision-making (SDM) should be used to ensure that patients are choosing their best treatment option. The goal was to develop and psychometrically test a brief instrument for assessing the patient's perspective of the SDM process during his or her clinical encounters with an HAE specialist/allergist. Method: We hypothesized that SDM could be used effectively to help patients in their choice of therapy for HAE. Ten HAE treating physicians from the United States with a total of 50 patients with HAE used SDM to help patients choose the best prophylactic therapies (oral kallikrein inhibitor, androgens, subcutaneous C1 inhibitor replacement therapy, intravenous C1 inhibitor replacement therapy, monoclonal antibody kallikrein inhibitor) for their HAE and then completed surveys to analyze the effectiveness of the implementation of SDM as a quality indicator in health services assessment. Results: The congruence of answers between the physicians and the patients was then analyzed; 90% of the patient-physician pairs agreed that the advantages and disadvantages of the treatment options were precisely explained; 92% of the patient-physician pairs agreed that the physician helped them understand all the information and that the physician asked them which treatment option they preferred; 88% of the pairs agreed that the different treatment options were thoroughly weighed and 92% of the pairs felt that they selected a treatment option together. Conclusion: In summary, SDM is being implemented by treating physicians to determine the best management options for their patients with HAE.

背景:遗传性血管性水肿(HAE遗传性血管性水肿(HAE)是一种复杂的疾病,有多种治疗方案可供选择。应采用共同决策(SDM)来确保患者选择最佳治疗方案。我们的目标是开发一种简短的工具并对其进行心理测试,以评估患者在与 HAE 专家/过敏学家的临床接触中对 SDM 过程的看法。方法:我们假设 SDM 可以有效帮助患者选择治疗 HAE 的方法。来自美国的 10 位治疗 HAE 的医生共接诊了 50 位 HAE 患者,他们使用 SDM 帮助患者选择治疗 HAE 的最佳预防疗法(口服降钙素抑制剂、雄激素、皮下 C1 抑制剂替代疗法、静脉注射 C1 抑制剂替代疗法、单克隆抗体降钙素抑制剂),然后填写调查问卷,分析作为医疗服务评估质量指标的 SDM 的实施效果。结果90%的医患双方一致认为医生准确解释了治疗方案的优缺点;92%的医患双方一致认为医生帮助他们了解了所有信息,医生询问了他们更倾向于哪种治疗方案;88%的医患双方一致认为对不同的治疗方案进行了全面权衡,92%的医患双方认为他们共同选择了一种治疗方案。结论总之,主治医生正在实施 SDM,以确定 HAE 患者的最佳治疗方案。
{"title":"The utility of shared decision making in the management of hereditary angioedema.","authors":"Rachel Odin, John Anderson, Joshua Jacobs, Douglas Jones, H Henry Li, William Lumry, Michael Manning, Daniel Soteres, Raffi Tachdjian, William Yang, Jonathan A Bernstein","doi":"10.2500/aap.2024.45.240071","DOIUrl":"https://doi.org/10.2500/aap.2024.45.240071","url":null,"abstract":"<p><p><b>Background:</b> Hereditary angioedema (HAE) is a complex disorder with a wide array of treatment options. Shared decision-making (SDM) should be used to ensure that patients are choosing their best treatment option. The goal was to develop and psychometrically test a brief instrument for assessing the patient's perspective of the SDM process during his or her clinical encounters with an HAE specialist/allergist. <b>Method:</b> We hypothesized that SDM could be used effectively to help patients in their choice of therapy for HAE. Ten HAE treating physicians from the United States with a total of 50 patients with HAE used SDM to help patients choose the best prophylactic therapies (oral kallikrein inhibitor, androgens, subcutaneous C1 inhibitor replacement therapy, intravenous C1 inhibitor replacement therapy, monoclonal antibody kallikrein inhibitor) for their HAE and then completed surveys to analyze the effectiveness of the implementation of SDM as a quality indicator in health services assessment. <b>Results:</b> The congruence of answers between the physicians and the patients was then analyzed; 90% of the patient-physician pairs agreed that the advantages and disadvantages of the treatment options were precisely explained; 92% of the patient-physician pairs agreed that the physician helped them understand all the information and that the physician asked them which treatment option they preferred; 88% of the pairs agreed that the different treatment options were thoroughly weighed and 92% of the pairs felt that they selected a treatment option together. <b>Conclusion:</b> In summary, SDM is being implemented by treating physicians to determine the best management options for their patients with HAE.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"434-437"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dupilumab rapidly improves eustachian tube dysfunction and otologic symptoms in aspirin-exacerbated respiratory disease. 杜匹单抗可迅速改善阿司匹林加重呼吸系统疾病患者的咽鼓管功能障碍和耳科症状。
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240047
Jyotsna Mullur, Marie Lundberg, Rie Maurer, Tanya M Laidlaw, Kathleen M Buchheit

Background: Patients with aspirin-exacerbated respiratory disease (AERD) frequently experience symptoms consistent with eustachian tube dysfunction (ETD), which can substantially impair patient quality of life. Methods: We analyzed a cohort of 98 adult patients with AERD who participated in a longitudinal, survey-based study. Results: By assessing data over 1 year, we established that, in patients with AERD, the ear/facial subdomain of the 22-item Sino-Nasal Outcome Test (SNOT-22) questionnaire could predict performance on the 7-item Eustachian Tube Dysfunction Questionnaire, a validated instrument for the diagnosis of ETD. We then performed a re-analysis of data from a prospective, open-label study of 22 adult patients with AERD treated with dupilumab for 3 months. We found that treatment with dupilumab was associated with a significant decrease in the SNOT-22 ear/facial subdomain score, which reflects a substantial reduction in otologic symptoms and ETD within 1 month of initiating dupilumab and was sustained for 3 months afterward. Conclusion: Our findings provide evidence that dupilumab significantly improved ETD and otologic symptoms in AERD, evidenced by changes in the SNOT-22 ear/facial subdomain score. The presence of ETD and otologic symptoms should be considered when determining the optimal therapeutic course for patients with AERD.

背景:阿司匹林加重呼吸道疾病(AERD)患者经常会出现与咽鼓管功能障碍(ETD)一致的症状,这会严重影响患者的生活质量。研究方法我们分析了参加一项纵向调查研究的 98 名咽鼓管功能障碍成年患者。结果通过评估一年来的数据,我们发现在咽鼓管反流病患者中,22 项中鼻结果测试(SNOT-22)问卷中的耳/面部子域可以预测 7 项咽鼓管功能障碍问卷的成绩,该问卷是用于诊断咽鼓管反流病的有效工具。随后,我们对一项前瞻性开放标签研究的数据进行了重新分析,该研究对 22 名患有咽鼓管扩张症的成年患者进行了为期 3 个月的杜普鲁单抗治疗。我们发现,使用杜必鲁单抗治疗后,SNOT-22 耳/面部子域评分显著下降,这反映出在开始使用杜必鲁单抗的 1 个月内,耳科症状和 ETD 大幅减少,并在之后的 3 个月内持续减少。结论我们的研究结果提供了证据,即通过 SNOT-22 耳/面部子域评分的变化,杜普鲁单抗可明显改善 AERD 患者的 ETD 和耳科症状。在确定 AERD 患者的最佳治疗方案时,应考虑 ETD 和耳科症状的存在。
{"title":"Dupilumab rapidly improves eustachian tube dysfunction and otologic symptoms in aspirin-exacerbated respiratory disease.","authors":"Jyotsna Mullur, Marie Lundberg, Rie Maurer, Tanya M Laidlaw, Kathleen M Buchheit","doi":"10.2500/aap.2024.45.240047","DOIUrl":"10.2500/aap.2024.45.240047","url":null,"abstract":"<p><p><b>Background:</b> Patients with aspirin-exacerbated respiratory disease (AERD) frequently experience symptoms consistent with eustachian tube dysfunction (ETD), which can substantially impair patient quality of life. <b>Methods:</b> We analyzed a cohort of 98 adult patients with AERD who participated in a longitudinal, survey-based study. <b>Results:</b> By assessing data over 1 year, we established that, in patients with AERD, the ear/facial subdomain of the 22-item Sino-Nasal Outcome Test (SNOT-22) questionnaire could predict performance on the 7-item Eustachian Tube Dysfunction Questionnaire, a validated instrument for the diagnosis of ETD. We then performed a re-analysis of data from a prospective, open-label study of 22 adult patients with AERD treated with dupilumab for 3 months. We found that treatment with dupilumab was associated with a significant decrease in the SNOT-22 ear/facial subdomain score, which reflects a substantial reduction in otologic symptoms and ETD within 1 month of initiating dupilumab and was sustained for 3 months afterward. <b>Conclusion:</b> Our findings provide evidence that dupilumab significantly improved ETD and otologic symptoms in AERD, evidenced by changes in the SNOT-22 ear/facial subdomain score. The presence of ETD and otologic symptoms should be considered when determining the optimal therapeutic course for patients with AERD.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"421-425"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrafiltered dog allergen skin test compared with acetone precipitated and conventional dog: A retrospective study. 超滤狗过敏原皮试与丙酮沉淀狗过敏原皮试和传统狗过敏原皮试的比较:回顾性研究
IF 2.6 3区 医学 Q2 ALLERGY Pub Date : 2024-11-01 DOI: 10.2500/aap.2024.45.240073
Joshua Pollock, Nora Watson, Luke Pittman, David Schwartz

Background: Various formulations of dog allergen extracts, including conventional dog (also known as dog epithelium) and acetone precipitated (AP) dog, have been used for skin-prick testing (SPT), with AP dog showing improved antigen content but experiencing stability issues due to precipitant formation. Ultrafiltered (UF) dog extract has been developed to address these concerns by offering comparable allergen content to AP dog. This study retrospectively compared UF dog with conventional dog and AP dog in SPT. Objective: To compare the efficacy of UF dog extract with conventional dog and AP dog extracts in detecting dog sensitization through SPT. Methods: Retrospective analysis of SPT results from a single U.S. allergy clinic was conducted. Tests performed between October 2022 and March 2024 were included. Primary and secondary outcomes were analyzed by using descriptive statistics and statistical tests. Results: UF dog, AP dog, and conventional dog showed positivity rates of 24.2%, 23.5%, and 16.3%, respectively. UF dog demonstrated significantly higher average wheal and erythema sizes compared with conventional dog and AP dog, but UF dog was not statistically different from AP dog in terms of test positivity. Conclusion: UF dog extract showed comparable number of positive tests to AP dog and a greater number of positive tests to conventional dog. Results of the study suggest UF dog as a viable alternative to AP dog, which offered improved stability and similar test responses. Further research with larger sample sizes is recommended to confirm these findings.

背景:各种狗过敏原提取物配方,包括传统狗(也称为狗上皮细胞)和丙酮沉淀(AP)狗,已被用于皮肤点刺试验(SPT)。为了解决这些问题,人们开发了超滤(UF)狗提取物,其过敏原含量与AP狗相当。本研究回顾性地比较了超滤狗与传统狗和 AP 狗在 SPT 中的表现。目的比较 UF 狗提取物与传统狗提取物和 AP 狗提取物在通过 SPT 检测狗致敏性方面的功效。方法:对 SPT 结果进行回顾性分析:对美国一家过敏诊所的 SPT 结果进行回顾性分析。研究纳入了 2022 年 10 月至 2024 年 3 月期间进行的测试。使用描述性统计和统计检验分析主要和次要结果。结果如下UF 狗、AP 狗和传统狗的阳性率分别为 24.2%、23.5% 和 16.3%。与传统犬和 AP 犬相比,UF 犬的平均疣体和红斑大小明显更高,但在检测阳性率方面,UF 犬与 AP 犬没有统计学差异。结论UF dog 提取物显示的阳性试验数量与 AP dog 相当,而与传统 dog 相比,UF dog 提取物显示的阳性试验数量更多。研究结果表明,UF dog 是 AP dog 的一种可行替代品,其稳定性更好,测试反应相似。建议进一步开展样本量更大的研究,以证实这些发现。
{"title":"Ultrafiltered dog allergen skin test compared with acetone precipitated and conventional dog: A retrospective study.","authors":"Joshua Pollock, Nora Watson, Luke Pittman, David Schwartz","doi":"10.2500/aap.2024.45.240073","DOIUrl":"10.2500/aap.2024.45.240073","url":null,"abstract":"<p><p><b>Background:</b> Various formulations of dog allergen extracts, including conventional dog (also known as dog epithelium) and acetone precipitated (AP) dog, have been used for skin-prick testing (SPT), with AP dog showing improved antigen content but experiencing stability issues due to precipitant formation. Ultrafiltered (UF) dog extract has been developed to address these concerns by offering comparable allergen content to AP dog. This study retrospectively compared UF dog with conventional dog and AP dog in SPT. <b>Objective:</b> To compare the efficacy of UF dog extract with conventional dog and AP dog extracts in detecting dog sensitization through SPT. <b>Methods:</b> Retrospective analysis of SPT results from a single U.S. allergy clinic was conducted. Tests performed between October 2022 and March 2024 were included. Primary and secondary outcomes were analyzed by using descriptive statistics and statistical tests. <b>Results:</b> UF dog, AP dog, and conventional dog showed positivity rates of 24.2%, 23.5%, and 16.3%, respectively. UF dog demonstrated significantly higher average wheal and erythema sizes compared with conventional dog and AP dog, but UF dog was not statistically different from AP dog in terms of test positivity. <b>Conclusion:</b> UF dog extract showed comparable number of positive tests to AP dog and a greater number of positive tests to conventional dog. Results of the study suggest UF dog as a viable alternative to AP dog, which offered improved stability and similar test responses. Further research with larger sample sizes is recommended to confirm these findings.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"45 6","pages":"453-455"},"PeriodicalIF":2.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Allergy and asthma proceedings
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1